Shalom Auerbach Sells 100,000 Shares of OS Therapies Inc (NYSE:OSTX) Stock

OS Therapies Inc (NYSE:OSTX) major shareholder Shalom Auerbach sold 100,000 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $2.84, for a total value of $284,000.00. Following the completion of the sale, the insider now owns 2,431,211 shares of the company’s stock, valued at approximately $6,904,639.24. This trade represents a 3.95 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Shalom Auerbach also recently made the following trade(s):

• On Wednesday, January 15th, Shalom Auerbach sold 16,720 shares of OS Therapies stock. The shares were sold at an average price of $6.74, for a total value of $112,692.80.

OS Therapies Stock Down 11.7 %

Shares of OSTX stock traded down $0.26 during mid-day trading on Tuesday, reaching $1.97. The stock had a trading volume of 1,001,666 shares, compared to its average volume of 2,153,116. The business’s fifty day moving average is $3.40 and its 200-day moving average is $3.16. OS Therapies Inc has a 1-year low of $1.58 and a 1-year high of $7.00.

Analyst Ratings Changes

OSTX has been the subject of a number of research analyst reports. D. Boral Capital reiterated a “buy” rating and issued a $20.00 price target on shares of OS Therapies in a research note on Thursday, January 30th. Maxim Group increased their price target on OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, January 16th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in OS Therapies stock. CM Management LLC grew its position in OS Therapies Inc (NYSE:OSTX) by 120.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 110,044 shares of the company’s stock after purchasing an additional 60,044 shares during the period. CM Management LLC owned approximately 0.51% of OS Therapies worth $471,000 at the end of the most recent quarter.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.